ARTICLES BY LOUIS

• Pastries And Process: A Recipe for Innovation At CDMOs

  11/27/2017

  Hard truths offset by soft skills make up the outsourced drug development and manufacturing industry. Here are some of those truths, skills, and their syntheses for innovation at CDMOs, from some accomplished biopharma professionals.

• Bigger Pharma Supports Biotech Outsourcing

  11/14/2017

  Mersana Therapeutics has a powerful weapon in its battle to combat supply-chain complexity: A collaborative partnership with Takeda’s Millennium. We’ll look at how Takeda assists this biotech in the contract development and manufacturing of drug candidates. Today more than ever, biotechs rely on this type of Bigger Pharma assistance. 

• You Can Do Everything Right, But Still Get Burned By Outsourcing

  11/3/2017

  This is a narrative of how a virtual biotech did everything in its power to execute on an outsourcing strategy, but still suffered a critical setback at its service provider, told be Marilyn Bruno, CEO of Aequor, Inc. 

• Lessons From Mersana's Outsourced Model For ADCs

  10/24/2017

  Antibody-drug conjugates (ADCs) are on the move in the regulatory approval pipeline. Time again for us to view this technology through our prism of external support systems to see what we can further learn about our industry. Luckily, we get that view through the eyes of Michael Kaufman, Senior Vice President of CMC for Cambridge, Mass-based Mersana Therapeutics. 

• Outsourcing Dreams In Latin America

  10/4/2017

  When Boehringer Ingelheim swapped its consumer healthcare assets with Sanofi, Edgardo Rodriguez went along, too. It was like walking to the other side of the street in his beloved Buenos Aires. And his “new” job at Sanofi runs down the same road: Manage a supply chain for a European pharmaceutical company that includes dozens of CDMOs throughout Latin America. 

• Boehringer Ingelheim And The Two Sides Of Biologics Outsourcing

  9/28/2017

  Jens Vogel, President & CEO, BI Fremont Inc., can’t help seeing two sides to most everything associated with the development and manufacturing of biologics. For example, he says we are in an era that at the same time can be dubbed “Death of the Blockbuster” and “Return of the Blockbuster.”

• How To Get Saved By A Drug Supply Chain

  9/14/2017

  "We’re there to help service providers continue to be healthy, viable businesses,” says Phil Roberts, Senior Vice President, Technical Operations, Orexigen. “I’m open to the concept that a static CDMO, is really a dead CDMO,” he concludes. But for Orexigen and its supply chain, it’s been much more of a mutually assured existence. Here’s part two of the journey. 

• Every Company Tells A Story: Orexigen, Anti-Obesity And Outsourcing

  9/6/2017

  Just like with pictures, every company tells a story. For its true grit and determination in the face of regulatory and market adversity, and its survival due to the ability to quickly establish a commercial supply chain and work with outsourcing partners, no company tells us a better story than Orexigen.

• Unleash Blockchain Technologies On The Entire Supply Chain

  8/28/2017

  Release blockchain technologies from the jaws of serialization. Unleash it on tech transfer, data integrity, project management, supply-chain relationships, and all components that make up our drug development and manufacturing outsourcing industry.

• Less Cost And More Control Limits Supply Chain Success

  8/18/2017

  Our industry would benefit from the sourcing function focusing less on narrow cost reductions, and more on broader corporate objectives; and from drug owners who allow external partners more control of their own environments. These would add up to a better functioning supply chain, and improved overall business outcomes.